Dexamethasone impairs hypoxia-inducible factor-1 function

被引:65
|
作者
Wagner, A. E. [1 ]
Huck, G. [1 ]
Stiehl, D. P. [1 ]
Jelkmann, W. [1 ]
Hellwig-Buergel, T. [1 ]
机构
[1] Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany
关键词
glucocorticoid receptor; HIF-1; repression; transcriptional cross-talk; nuclear import; transrepression; heat-shock protein 90; wound healing;
D O I
10.1016/j.bbrc.2008.05.061
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription-factor composed of alpha-and beta-subunits. HIF-1 is not only necessary for the cellular adaptation to hypoxia, but it is also involved in inflammatory processes and wound healing. Glucocorticoids (GC) are therapeutically used to suppress inflammatory responses. Herein, we investigated whether GC modulate HIF-1 function using GC receptor (GR) possessing (HepG2) and GR deficient (Hep3B) human hepatoma cell cultures as model systems. Dexamethasone (DEX) treatment increased HIF-1 alpha levels in the cytosol of HepG2 cells, while nuclear HIF-1 alpha levels and HIF-1 DNA-binding was reduced. In addition, DEX dose-dependently lowered the hypoxia-induced luciferase activity in a reporter gene system. DEX suppressed the hypoxic stimulation of the expression of the HIF-1 target gene VEGF(vascular endothelial growth factor) in HepG2 cultures. DEX did not reduce hypoxically induced luciferase activity in HRB5 cells, a Hep3B derivative lacking GR. Transient expression of the GR in HR135 cells restored the susceptibility to DEX. Our study discloses the inhibitory action of GC on HIF-1 dependent gene expression, which may be important with respect to the impaired wound healing in DEX-treated patients. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:336 / 340
页数:5
相关论文
共 50 条
  • [31] The Role of Hypoxia-Inducible Factor-1α in Acetaminophen Hepatotoxicity
    Sparkenbaugh, Erica M.
    Saini, Yogesh
    Greenwood, Krista K.
    LaPres, John J.
    Luyendyk, James P.
    Copple, Bryan L.
    Maddox, Jane F.
    Ganey, Patricia E.
    Roth, Robert A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (02): : 492 - 502
  • [32] Copper Regulation of Hypoxia-Inducible Factor-1 Activity
    Feng, Wenke
    Ye, Fei
    Xue, Wanli
    Zhou, Zhanxiang
    Kang, Y. James
    MOLECULAR PHARMACOLOGY, 2009, 75 (01) : 174 - 182
  • [33] Hypoxia-Inducible Factor-1α and Autoimmune Lupus, Arthritis
    Yang, Zu-Cheng
    Liu, Yi
    INFLAMMATION, 2016, 39 (03) : 1268 - 1273
  • [34] Skeletal muscle hypoxia-inducible factor-1 and exercise
    Lindholm, Malene E.
    Rundqvist, Helene
    EXPERIMENTAL PHYSIOLOGY, 2016, 101 (01) : 28 - 32
  • [35] Synthesis of Neolamellarin A, an Inhibitor of Hypoxia-inducible Factor-1
    Arafeh, Khaled M.
    Ullah, Nisar
    NATURAL PRODUCT COMMUNICATIONS, 2009, 4 (07) : 925 - 926
  • [36] Honokiol inhibits hypoxia-inducible factor-1 pathway
    Lan, Keng-Li
    Lan, Keng-Hsin
    Sheu, Meei-Ling
    Chen, Ming-Yuan
    Shih, Yi-Sheng
    Hsu, Fu-Chih
    Wang, Hong-Ming
    Liu, Ren-Shyan
    Yen, Sang-Hue
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2011, 87 (06) : 579 - 590
  • [37] Hypoxia-inducible factor-1α and the glycolytic phenotype in tumors
    Robey, IF
    Lien, AD
    Welsh, SJ
    Baggett, BK
    Gillies, RJ
    NEOPLASIA, 2005, 7 (04): : 324 - 330
  • [38] Hypoxia-inducible factor-1α regulation of myeloid cells
    C. L. Stothers
    L. Luan
    B. A. Fensterheim
    J. K. Bohannon
    Journal of Molecular Medicine, 2018, 96 : 1293 - 1306
  • [39] Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
    Li, Y.
    Ye, D.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (07) : 782 - 796
  • [40] Hypoxia-Inducible Factor-1 in Multiple Myeloma Progression
    Ria, Roberto
    Reale, Antonia
    Berardi, Simona
    Piccoli, Claudia
    Di Pietro, Giulia
    Basile, Antonio
    Capitanio, Nazareno
    Vacca, Angelo
    BLOOD, 2009, 114 (22) : 720 - 720